Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 43 of 43 publications.

Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8

Beau-Lejdstrom R, Hong LS, Garcia de Albeniz X, Floricel F, Lorenzen J, Bonfitto F, Kalilani L, Loesch C, Luscombe G, Perez-Gutthann S, Mottet I, Foskett N. Incidence of acute renal failure in patients using Levetiracetam versus other antiseizure medications: a voluntary post-authorization safety study. Drug Saf. 2022 Jul;45(7):781-90. doi: 10.1007/s40264-022-01193-0

Flythe JE, Forfang D, Gedney N, White DM, Wilkie C, Cavanaugh K, Harris RC, Unruh M, Squillaci G, West M, Mansfield C, Soloe CS, Treiman K, Wood D, Hurst FP, Neuland C, Saha A, Sheldon M, Tarver ME. Development of a patient preference survey for wearable kidney replacement therapy devices. Kidney360. 2022 May 5;3(7):1197-209. doi: 10.34067/KID.0001862022

Chebib FT, Zhou X, Garbinsky D, Davenport E, Sasikiran N, Oberdhan O, Fernandes A. Pooled data analysis of the long-term effect of Tolvaptan in patients between 56 and 65 years with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Poster presented at the National Kidney Foundation Spring Clinical Meetings; April 6, 2022. Boston, MA.

Zhou X, Davenport E, Ouyang J, Hoke ME, Garbinsky D, Agarwal I, Krasa HB, Oberdhan D. Pooled data analysis of the long-term treatment effects of tolvaptan in ADPKD. Kidney Int Rep. 2022 Feb 19;7(5):1037-48. doi: 10.1016/j.ekir.2022.02.009

Fliser D, Portoles J, Houghton K, Ainsworth C, Blogg M, Lorenzo MM. Treatment structures and resource use in non-dialysis-dependent CKD patients (NDD-CKD) with renal anemia: a retrospective analysis. Poster presented at the Kongress fur NepHROlogie 2021 13th Annual Meeting; September 23, 2021.

Fliser D, Portoles J, Houghton K, Ainsworth C, Blogg M, Lorenzo MM. Treatment of anaemia with erythropoiesis-stimulating agents (ESAs) and concomitant therapies among patients with non-dialysis dependent chronic kidney disease (NDD-CKD) in Germany, Spain and the UK: a retrospective chart review. Poster presented at the 2021 58th ERA-EDTA Virtual Congress; June 5, 2021.

Mader G, Mladsi (she/her) D, Zhou X, Sanon M, Wang J, Willey C, Seliger S. Racial differences in mortality rates among elderly Non-ESRD CKD and ESRD patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): study findings using data from the USRDS. Poster presented at the Virtual National Kidney Foundation 2021 Spring Clinical Meetings; April 2021.

Layton JB, McGrath LJ, Sahrmann JM, Ma Y, Dharnidharka VR, O'Neil C, Weber DJ, Butler AM. Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Layton JB, McGrath LJ, Sahrmann JM, Dharnidharka VR, O'Neil CA, Butler AM. Plotting daily incidence of influenza vaccine reactions among patients with end-stage renal disease to inform study design decisions. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

McGrath LJ, Layton JB, Sahrmann JM, Dharnidharka VR, OʼNeil CA, Butler AM. Utilization of a booster dose of influenza vaccine among adults with end-stage renal disease in the United States. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Layton JB, McGrath LJ, Sahrmann JM, Ma Y, Dharnidharka VR, O’Neil C, Weber DJ, Butler AM. Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease. Vaccine. 2020 Jun 6;38(33):5178-86. doi: 10.1016/j.vaccine.2020.06.020

Zhou X, Garbinsky D, Ouyang J, Davenport E, Agarwal I, Oberdhan D. Longitudinal data on treatment duration and compliance from autosomal dominant polycystic kidney disease clinical trials with tolvaptan. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa139.S. doi: 10.1093/ndt/gfaa139.SO093

Zhou X, Davenport E, Ouyang J, Hoke M, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across an expanded pooled database of multiple autosomal dominant polycystic kidney disease clinical studies. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa142.P. doi: 10.1093/ndt/gfaa142.P0037

Zhou X, Davenport EK, Ouyang J, Krasa H, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across a pooled database of multiple Autosomal Dominant Polycystic Kidney Disease (ADPKD) clinical studies. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):663.

Mader G, Purser M, Mladsi D, Sanon M, Oberdhan D, Watnick T, Seliger S. Benefit of tolvaptan on time to End-stage Renal Disease (ESRD) for patients with rapidly progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD): a disease progression model. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):603.

Butler AM, Layton JB, Dharnidharka VR, McGrath LJ. Correspondence: In reply to 'High-dose versus standard-dose influenza vaccine in hemodialysis patients'. Am J Kidney Dis. 2020 Mar;75(3):456-7. doi: 10.1053/j.ajkd.2019.11.002

Butler AM, Layton JB, Dharnidharka VR, Sahrmann J, Seamans MJ, Weber DJ, McGrath L. Comparative effectiveness of high-dose versus standard-dose influenza vaccine among patients receiving maintenance hemodialysis. Am J Kidney Dis. 2020 Jan;75(1):72-83. doi: 10.1053/j.ajkd.2019.05.018.

Butler AM, Layton JB, Dharnidharka VR, Sahrmann J, Weber DJ, McGrath L. Comparative effectiveness of high-dose versus standard-dose influenza vaccine among patients on chronic hemodialysis. Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug 20; 28(S2):485. doi: 10.1002/pds.4864

Christiansen S, Christensen S, Pedersen L, Gammelager H, Layton JB, Brookhart MA, Christiansen CF. Timing of renal replacement therapy and long-term risk of chronic kidney disease and death in intensive care patients with acute kidney injury. Crit Care. 2017 Dec 28;21(1):326. doi: 10.1186/s13054-017-1903-y

Christiansen S, Christensen S, Pedersen L, Gammelager H, Layton JB, Brookhart MA, Christiansen CF. Timing of renal replacement therapy and long-term risk of chronic kidney disease and death in intensive care patients with acute kidney injury. Poster presented at the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(S2):370-1.

Raghunathan K, Layton JB, Ohnuma T, Shaw AD. Observational research using propensity scores. Adv Chronic Kidney Dis. 2016 Nov;23(6):367-72. doi: 10.1053/j.ackd.2016.11.010

Rak EC, Hooper SR, Belsante MJ, Burnett O, Layton B, Tauer D, Mantoo B, DeWalt D, Ferris ME. Caregiver word reading literacy and health outcomes among children treated in a pediatric nephrology practice. Clin Kidney J. 2016 Jun;9(3):510-5. doi: 10.1093/ckj/sfw015

Traina SB, McQuarrie K, Barrett A, DiBenedetti D, McLeod L. Content validity of the current health satisfaction questionnaire (CHES-Q) among people living with type 2 diabetes mellitus and comorbid chronic kidney disease (CKD). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

DaCosta Byfield S, McPheeters JT, Burton T, Nagar SP, Hackshaw MD. Persistence and compliance among US patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma. J Manag Care Pharm. 2015 Jun;21(6):515-22.

Hansen RN, Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, Ramsey SD. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Pharm. 2015 Jan;21(1):37-44.

Davis AE, Mehrotra S, Kilambi V, Kang J, McElroy L, Lapin B, Holl J, Abecassis M, Friedewald JJ, Ladner DP. The effects of the statewide sharing variance on geographic disparity in kidney transplantation in the United States. Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1149-60.

Hackshaw MD, Nagar SP, Parks DC, Miller LA. Persistence and compliance with Pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database. J Manag Care Pharm. 2014 Jun;20(6):603-10.

Copley-Merriman K, Olanrewaju B, Hogue S. The temporal relationship between NSAIDS and risk of gastrointestinal, cardiovascular, and renal events: a systematic review. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2, 2013. [abstract] Value Health. 2013 May; 16(3):A110.

Ferguson JE3rd, Goyal RK, Raynor MC, Nielsen ME, Pruthi RS, Brown PM, Wallen EM. Cost analysis of robot-assisted laparoscopic versus hand-assisted laparoscopic partial nephrectomy. J Endourol. 2012 Aug;26(8):1030-7.

Lang K, Meyers JL, Kovacs B, Candrilli SD. Renal impairment in patients with type 2 diabetes mellitus and associated antihyperglycemic medication adjustment: evidence from an electronic medical records database. Poster presented at the 43rd Annual Meeting and Scientific Exposition of the American Society of Nephrology; November 2010.

Layton JB, Hogan SL, Jennette CE, Kenderes B, Krisher J, Jennette JC, McClellan WM. Discrepancy between Medical Evidence Form 2728 and renal biopsy for glomerular diseases. Clin J Am Soc Nephrol. 2010 Nov;5(11):2046-52. doi: 10.2215/CJN.03550410.

Davis AE, Ladner D, Friedewald J. Analysis of dialysis center locations in Illinois. Poster presented at the American Transplant Congress; May 2010.

Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Rothman KJ, Fischer M, Mehta J, Winkelmayer WC. The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol. 2008 Jul 1;19(7):1389-95.

Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF. Relative mortality and epoetin alfa dose in hemodialysis patients - Reply. Am J Kidney Dis. 2008 May 1;51(5):865-6.

Pearson IV, Johnson KI. A cost minimization analysis of epoetin zeta for the treatment of anemia associated with chronic kidney disease. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. [abstract] Value Health. 2008 May; 11(3):A304.

Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis. 2008 Jan 1;51(1):62-70.

Bernardo M, Globe D, Kewalramani R, Masaquel CJ. Costs of anemia management in chronic disease (CKD) from the perspective of the payor, patient, and family. Poster presented at the American Society of Nephrology; November 2006.

Miller DP, Kaye JA, Shea K, Ziyadeh N, Cali C, Black C, Walker AM. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology. 2004 Mar 1;15(2):208-15.

Rivero E, Alexander M, Iribarren C, Ordoñez J, Shandling M, Go AS. Lipid monitoring and lipid profiles in kidney transplant patients within a large health maintenance organization: 1995-1999. Poster presented at the American Transplant Congress; May 2003. Washington, DC.

Bell T, Candrilli S, Irish W, Morris E, Cairo MS. Medical resource use and costs associated with renal complications among patients with hematologic malignancies. Blood. 2002 Jan 1;100(11):221A.

Middleton JP, Mangel AW, Basavappa S, Fitz JG. Nucleotide receptors regulate membrane ion transport in renal epithelial cells. Am J Physiol. 1993 May;264(5 Pt 2):F867-73.

Lanes SF, Delzell E, Dreyer NA, Rothman KJ. Analgesics and kidney disease. Int J Epidemiol. 1986 Dec;15(4):454-5. doi: 10.1093/ije/15.4.454